Takeda Pharmaceutical Company Limited
TAK · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$11,729 | $124,279 | -$103,200 | $23,789 |
| Dep. & Amort. | $184,982 | $181,636 | $189,769 | $186,955 |
| Deferred Tax | $39,903 | $26,351 | $0 | $0 |
| Stock-Based Comp. | $18,731 | $16,531 | $17,627 | $18,300 |
| Change in WC | $21,938 | -$33,701 | -$7,457 | $69,128 |
| Other Non-Cash | $124,403 | -$99,673 | $125,420 | $85,584 |
| Operating Cash Flow | $378,228 | $215,423 | $222,159 | $383,756 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$40,095 | -$47,913 | -$48,793 | -$45,088 |
| Net Acquisitions | $417 | $29,291 | $0 | $0 |
| Inv. Purchases | -$1,550 | -$215 | $0 | $0 |
| Inv. Sales/Matur. | $2,882 | $1,128 | $0 | $0 |
| Other Inv. Act. | -$9,787 | -$15,484 | $29,112 | -$70,467 |
| Investing Cash Flow | -$48,133 | -$33,193 | -$19,681 | -$115,555 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $36,555 | $22 | -$547,992 | -$470,878 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | $2 | -$51,603 | -$49,978 | $0 |
| Dividends Paid | -$8,787 | -$145,295 | -$9,738 | -$145,451 |
| Other Fin. Act. | -$39,751 | -$18,024 | $305,916 | -$39,640 |
| Financing Cash Flow | -$11,981 | -$214,900 | -$301,792 | -$655,969 |
| Forex Effect | $13,364 | -$2,435 | -$9,700 | $22,879 |
| Net Chg. in Cash | $331,478 | -$35,105 | -$109,013 | -$364,889 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $350,008 | $385,113 | $494,126 | $859,015 |
| End Cash | $681,486 | $350,008 | $385,113 | $494,126 |
| Free Cash Flow | $325,403 | $140,355 | $173,366 | $338,668 |